Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2

• Published in: Biochemical and biophysical research communications Vol. 394; no. 1; pp. 54 - 58
• Main Authors: Kanagawa, Naoko, Yanagawa, Tatsuya, Mukai, Yohei, Yoshioka, Yasuo, Okada, Naoki, Nakagawa, Shinsaku
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.03.2010
• Subjects: Adoptive immunotherapy; Animals; Cell Line, Tumor; Cytotoxic T lymphocyte; Genetic Engineering; Immunotherapy, Adoptive - methods; Mice; Mice, Inbred C57BL; Neoplasms - immunology; Neoplasms - therapy; scFv; Single-Chain Antibodies - biosynthesis; Single-Chain Antibodies - genetics; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - transplantation; Targeting; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; Vascular Endothelial Growth Factor Receptor-2 - immunology; VEGFR2; VEGFR2; PBS; TCR; IL; Targeting; VEGF; Adoptive immunotherapy; gp; mAb; VH; scFv; FBS; VL; scFv-CTL; CTL; OVA; Cytotoxic T lymphocyte

Cytotoxic T lymphocytes (CTL) are critical effector cells in tumor immunity. Adoptive transfer therapy with in vitro-expanded tumor-specific CTL is a promising approach for preventing cancer metastasis and recurrence. Transferred CTL are not effective in clinical trials, however, due to inadequate t...